» Articles » PMID: 29685593

Routine Immunization Services Costs and Financing in China, 2015

Overview
Journal Vaccine
Date 2018 Apr 25
PMID 29685593
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To estimate the costs of routine immunization (RI) services in China in 2015, to provide objective data relevant to investment in the Expanded Program on Immunization, and to contribute to global data on costing and financing of RI.

Methods: The study was conducted between January and March 2016. We selected 276 villages, 138 townships, 46 counties, and 40 prefectures from 15 provinces as investigation sites at random, stratified by eastern, middle, and western regions. Direct cost items included vaccines, personnel, cold chain, surveillance, communication, training, and supervision at the national, provincial, prefecture, county, township, and village levels. We obtained financial data from governmental and external sources. Indirect costs of RI included parents' transportation costs and productivity lost due to taking their children for vaccination.

Results: Total direct costs were $92.42 for each child fully immunized ($4.20/dose), which equates to $1529.55 million per birth cohort. RI costs were higher in the eastern region than in the western region, and higher than that of the central region. Vaccination coverage was positively associated with direct routine immunization costs. The cost of the recommended vaccines was $19.08/child and vaccine only accounted for 20.64% of total costs. Operational cost, including surveillance, communication, training and supervision, was $217.31/child, accounting for 14.21% of total cost. The indirect cost per child was $72.86; the total indirect cost was $1205.83 million for the birth cohort. Government investment in RI accounted for about 70% of total costs. Revenue from sales of private-sector vaccine supported the remaining 30% of RI costs.

Conclusions: While government financing has increased, some operating costs continue to be provided from revenue generated by sales of Category 2 (private-sector) vaccines to families. China could benefit from bringing new and underutilized vaccines into the EPI system based on evidence that includes routine immunization vaccine and operations costs.

Citing Articles

Cost-effectiveness analysis of switching from a bivalent to a nonavalent HPV vaccination programme in China: a modelling study.

Gao M, Hu S, Zhao X, You T, Hong Y, Liu Y Lancet Reg Health West Pac. 2025; 56:101499.

PMID: 40061912 PMC: 11889945. DOI: 10.1016/j.lanwpc.2025.101499.


Economic evaluation on meningococcal vaccination strategies among children under nine years of age in Zhejiang province, China.

Shen J, Ji C, Luo X, Hu Y PLoS One. 2024; 19(9):e0310274.

PMID: 39250492 PMC: 11383224. DOI: 10.1371/journal.pone.0310274.


Cost-effectiveness analysis of vaccination strategies against meningococcal disease for children under nine years of age in China.

Zhang H, Zhang H, Fang H Hum Vaccin Immunother. 2024; 20(1):2313872.

PMID: 38348600 PMC: 10865926. DOI: 10.1080/21645515.2024.2313872.


Adding new childhood vaccines to China's National Immunization Program: evidence, benefits, and priorities.

Zhang H, Lai X, Patenaude B, Jit M, Fang H Lancet Public Health. 2023; 8(12):e1016-e1024.

PMID: 38000881 PMC: 10695764. DOI: 10.1016/S2468-2667(23)00248-7.


Construction of an indicator framework for vaccine inclusion in public health programs: A Delphi-entropy method study.

Wang Q, Dai P, Jia M, Jiang M, Li J, Yang W Hum Vaccin Immunother. 2023; 19(3):2272539.

PMID: 37905961 PMC: 10760382. DOI: 10.1080/21645515.2023.2272539.